Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 36 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Teacher Battling Cancer Gifted Free School Supplies August 25, 2021 Women in Science: Celebrating with our Women of Influence initiative March 15, 2023 Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... January 28, 2022 The rise of the ‘long-waiter’ – why cancer waiting times are... November 10, 2022 Load more HOT NEWS Exposure to Antibiotics, Specifically Fluoroquinolones, Before Treatment with Immune Checkpoint Inhibitor... GreaterGood Has Donated More Than 2 Million Masks to Frontline Workers... Enfortumab Vedotin Approved for Recurrent Bladder Cancer EMA Recommends Granting a Marketing Authorisation for Generic Dasatinib
